The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes
|
|---|---|
| Published in |
Frontiers in Pharmacology, November 2017
|
| DOI | 10.3389/fphar.2017.00798 |
| Pubmed ID | |
| Authors |
Sachin V Suryavanshi, Yogesh A Kulkarni |
| Abstract |
Diabetes is a metabolic disorder affecting large percentage of population worldwide. NF-κβ plays key role in pathogenesis of vascular complications of diabetes. Persistent hyperglycemia activates NF-κβ that triggers expression of various cytokines, chemokines and cell adhesion molecules. Over-expression of TNF-α, interleukins, TGF-β, Bcl2 and other pro-inflammatory proteins and pro-apoptotic genes by NF-κβ is key risk factor in vascular dysfunction. NF-κβ over-expression also triggers calcification of endothelial cells leading to endothelial dysfunction and further vascular complications. Inhibition of NF-κβ pro-inflammatory pathway is upcoming novel target for management of vascular complications of diabetes. Various natural and synthetic inhibitors of NF-κβ have been studied in management of diabetic complications. Recent preclinical and clinical studies validate NF-κβ as promising target in the management of vascular complications of diabetes. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 279 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 279 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 26 | 9% |
| Student > Master | 26 | 9% |
| Student > Bachelor | 24 | 9% |
| Other | 18 | 6% |
| Student > Doctoral Student | 17 | 6% |
| Other | 52 | 19% |
| Unknown | 116 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 51 | 18% |
| Biochemistry, Genetics and Molecular Biology | 37 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 23 | 8% |
| Agricultural and Biological Sciences | 7 | 3% |
| Immunology and Microbiology | 6 | 2% |
| Other | 29 | 10% |
| Unknown | 126 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 November 2017.
All research outputs
#20,451,991
of 23,007,887 outputs
Outputs from Frontiers in Pharmacology
#10,212
of 16,313 outputs
Outputs of similar age
#288,849
of 331,365 outputs
Outputs of similar age from Frontiers in Pharmacology
#171
of 282 outputs
Altmetric has tracked 23,007,887 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,313 research outputs from this source. They receive a mean Attention Score of 5.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,365 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 282 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.